Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3129-3137

  Mimae, T ^a,b   Tsuta, K ^a   Kondo, T ^a   Nitta, H ^c   Grogan, T M ^c   Okada, M ^b   Asamura, H ^a   Tsuda, H ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Gene copy number; Insulin like growth factor 1 receptor; Thymic carcinoma; Thymoma; Tyrosine kinase receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C;

ADULT; ARTICLE; BRIGHT FIELD IN SITU HYBRIDIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENE DOSAGE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; THYMOMA; THYMUS CANCER;

EID: 84869849422     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds147     Document Type: Article

References (32)

1. Hosaka Y, Tsuchida M, Toyabe S et al. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 2010; 89: 912-917.
2. Okumura M, Ohta M, Tateyama H et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624-632.
3. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-5557.
4. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-173.
5. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
6. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
7. Zhang YW, Staal B, Essenburg C et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010; 70: 6880-6890.
8. Tu WH, Zhu C, Clark C et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010; 10: 556.
9. Toms SA, Hercbergs A, Liu J et al. Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. J Neurosurg 1998; 88: 884-889.
10. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9: 1544-1553.
11. Ionescu DN, Sasatomi E, Cieply K et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005; 103: 630-636.
12. Aisner SC, Dahlberg S, Hameed MR et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol 2010; 5: 885-892.
13. Girard N, Teruya-Feldstein J, Payabyab EC et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010; 5: 1439-1446.
14. Zucali PA, Petrini I, Lorenzi E et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010; 116: 4686-4695.
15. Travis WD, Brambilla E, Muller-Hermelink HK et al. Pathology and genetics of tumors of the lung, pleura, thymus and heart. In: World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
16. Tsuta K, Kozu Y, Mimae T et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012; 7: 331-339.
17. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
18. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006; 1: 19.
19. Mimae T, Tsuta K, Takahashi F et al. Steroid receptor expression in thymomas and thymic carcinomas. Cancer 2011; 117: 4396-4405.
20. Dziadziuszko R, Merrick DT, Witta SE et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28: 2174-2180.
21. Imsumran A, Adachi Y, Yamamoto H et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 2007; 28: 947-956.
22. Pectasides E, Rampias T, Kountourakis P et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17: 2947-2954.
23. Szabo B, Nelhubel GA, Karpati A et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 2011; 47: 487-496.
24. Kelly RJ, Petrini I, Rajan A et al. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011; 29: 4820-4827.
25. Kashihara M, Azuma K, Kawahara A et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 2009; 4: 1066-1074.
26. Hoff K, Jorgensen JT, Muller S et al. Visualization of FISH Probes by dual-color chromogenic in situ hybridization. Am J Clin Pathol 2010; 133: 205-211.
27. Kato N, Itoh H, Serizawa A et al. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int 2010; 60: 510-515.
28. Gong Y, Yao E, Shen R et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009; 4: e7273.
29. Breinig M, Mayer P, Harjung A et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res 2011; 17: 2237-2249.
30. Bourhis J, Rivera F, Mesia R et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-2872.
31. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
32. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.